
Supplementary Information (SI) for RSC Advances.
This journal is © The Royal Society of Chemistry 2025
Supplementary Materials for:
Exploring the Potential Molecular Targets and Therapeutic Mechanisms of
Cyperi Rhizoma in Treating Diabetic Cardiomyopathy: A Computational
Approach
Su-Rui Lu¹#, Zi-Xiang Fu¹#, Yan Xia¹#, Yan-Mei Xu¹, Feng-Liang Wang³, Zhao-Wen
Pan¹, Yi-Wei Tu¹, Wen-Jing Peng¹, Ming-Li Han¹, Wei Yu¹*, Wen-Liang Zha,¹,²*
¹School of Pharmacy, Xianning Medical College, Hubei University of Science and
Technology, Xianning 437100, China.
²Second Affiliated Hospital, Xianning Medical College, Hubei University of Science
and Technology, Xianning 437100, China.
³Minda Hospital of Hubei Minzu University, En shi 445000, China.
#SuRui Lu, Zi-Xiang Fu, and Yan Xia are the co-first authors of this paper.
*Corresponding to:
Wen-Liang Zha, Xianning Medical College, Hubei University of Science and
Technology, No.88, Xiannng Avenue, Xianning 437100, China. E-mail:
xyzwl800@163.com.
Wei Yu, Xianning Medical College, Hubei University of Science and Technology,
No.88, Xiannng Avenue, Xianning 437100, China. E-mail: yuwei0805@163.com
TNF SIGNALING PATHWAY
Leukocyte recruitment
clAP1/2
cIAP1/2 degradation
Ccl2
Cel5
Ccl20
Cxcll
Cxcl2
Cxcl3
MAPK
+u
signaling pathway
Cxcl5
Cxcl10
Cx3ell
ASKI
Leukocyte activation
TAB1/2/3
MKK4/7
JNK1/2
AP-1
Csfl
Csf2
TRAF2/5
TAKI
TNF
TNFR1
TRADD
+p
+p
Surface receptors
RIP1
MKK3/6
p38
c/EBPβ
Fas
IL18R1
Jagl
DNA
Tpl2
Inflammatory cytokines
NF-kB
MSK1/2
CREB
SODD
NIK
+p
IL1b
IL6
IL15
Lif
Tnf
TNF
MEK1
ERK1/2
Intracellular
signaling
(negative)
Shedding
Ubiquitin mediated
+p
Bel3
Nfkbia
Socs3
Tnfaip3
Trafl
proteolysis
TACE
IkBa
iRhom
IKKB
IkBa ubiquitination
Intracellular signaling (positive)
iTAP
IKKα
and degradation
Ifi47
IKKy
NF-kB
Transcription factors
DNA
Deubiquitination
NF-kappa
Fos
Jun
JunB
CYLD
+p
signaling pathway
Remodeling of extracellular matrix
Mmp3
Mmp9
Mmp14
ITCH
c-FLIP
Vascular effects
Ednl
Vegfc
Ripoptosome
Apoptosis
PRRS
RIPI
+p,
CASP7
FADD
CASP810
Apoptosis
Nod2
RIP3
CASP3
Cell adhesion
Icaml
Sele
Vcaml
XIAP
Synthesis of inflammatory mediators
Necrosome
Ptgs2
+p
RIP1
RIP3
MLKL
PGAM5L
Drpl
Necroptosis
PGAM5S
PI3K-Akt
signaling pathway
PI3K
Akt
+p
NF-kB
+p
+p
NIK
IKKs
IkBa
Degradation
(Limited expression)
TRAF1
+p
INF/LTA
TNFR2
TRAF2
clAP1/2
RIP
MKK3
p38
Cell survival
TRAF3
+p
AIPI
JNK
e-Jun
Apoptosis
IRF1
-0
IFNB
DNA
04668 5/20/24
(c) Kanehisa Laboratories
Figure S1 Map of TNF signaling pathway
AGE-RAGE SIGNALING PATHWAY IN DIABETIC COMPLICATIONS
p27
Cell hypertrophy
ECM production
+p
FN
TOF-B
TOFBRI
Smad2/3
COL
Mesangial matrix expansion
TGFBRII
TGF -beta
**
DNA
TOF-B1
signaling pathway
Smad4
AGT
ATIR
Renin- -angiotensin
MAPK
system
signaling pathway
ROS
DNAO
TGF-B1
+p
O
RAGE
Calcium signaling
ERK1/2
Positive feedback
NADPH
pathway
AP-1
VEGF
Angiogenesis
DAG
PLC
PKC
p38
MCP-1
PAI-1
SELE
Thrombogenesis,
DNA
inflammation,
VCAM-
ICAM-1
MMP2
atherosclerosis
IP3
Ca'
Aging
IL-1
IL-6
IL-8
Inflammation
Inflammation
Oxidative Stress
p21 RAS
JNK
NF-kB
TNF-a
TF
ENDI
Dia-1
Ischemia -reperfusion
THBD
High glucose O
ROS
RAGE
AGEs
Akt
NADPH
PI3K
FOX01
PI3K-AKT
Cer
JNK
Bel-2
Apoptosis
signaling pathway
NOS
p38
CASP3
Bax
Pim-1
DNA
Jak-STAT
siganling pathway
+p
STAT3
NFATe1
Vascular remodeling
DNA
+p
JAK2
+p
STAT1,3
COLI
DNA
Cell cycle
STAT5
O
CycD1
DNA
Cellular proliferation leading to renal hypertrophy
CDK4
Hypoxia
RAGE
PKCBH
JNK
Egr-1
>0
Expression Egr-1
dependent genes
Vascular dysfunction
AGEs
DNA
04933 1/29/19
(c) Kanchisa Laboratories
Figure S2 Map of AGE-RAGE signaling pathway in diabetic complications
ARG-328
2.6
2.3
2.2
ALA 329
26
2.2
TYR-326
2.8
2.2
TYR-38
center_X = 6.29 center_Y = - 7.941 center_Z = 17.261 Binding energy = -5.6
size_X=75.25 size_Y=75.25
size= 75.25
Figure S3 Molecular docking between AKT1 and its natural ligand PIP3
A
0.5
AKT1
B
0.7
AKT1
AKT1-quercetin
0.6
AKT1-quercetin
0.4
0.5
0.3
RMSD (nm)
RMSF (nm)
0.4
0.3
0.2
0.2
0.1
0.1
0.0
0.0
0
20
40
60
80
100
0
100
200
300
400
Time (ns)
Residue
C
220
D
2.25
AKT1
AKT1
AKT1-quercetin
AKT1-quercetin
2.20
SASA (nm²)
200
Rg (nm)
2.15
180
2.10
160
2.05
0
20
40
60
80
100
0
20
40
60
80
100
Time (ns)
Time (ns)
E
F
6
AKT1 quercetin
Contribution Energy (KJ/mol)
0
5
Number of H-bond
4
3
2
Contribution Energy
-5
(KJ/mol)
-10
1
0
-15
0
20
40
60
80
100
TRP80R81HR82
Time (ns)
Residue
Figure S4 Analysis of MDS Results
(A) RMSD of AKT1-quercetin.(B) RMSF of AKT1-quercetin.(C) SASA of AKT1-quercetin.(D)
Rg changes of AKT1-quercetin.(E) Number of Hydrogen Bonds (HBNUM) of AKT1-quercetin.(F)
Free Energy Decomposition of Amino Acids for AKT1-quercetin.
Table S1 Protein ligand MMPBSA analysis
Energy
complex
Van der Waals Energy (KJ/mol)
-156.766
Electrostatic energy (kJ/mol)
-75.610
Polar solvation energy (KJ/mol)
161.970
Nonpolar solvation Energy(KJ/mol)
-19.120
Total Binding Energy(KJ/mol)
-89.526
-TAS(KJ/mol)
4.473
Total Binding Free Energy(KJ/mol)
-85.053
#
#
150
#
*
#
Cell viability (%)
100
50
0
Control DM+ DM (20HM)
Figure S5 Impact of quercetin and luteolin on H9c2 cardiomyocytes in a
diabetic environment
Influence of quercetin and luteolin on the survival rate of H9c2 myocardial cells subjected to
injury from high glucose and PA, as relative to the Control group, *P < 0.05; and relative to the
DM group, #P < 0.05, n=3 different cell batches. * indicates that there is a correlation between
two variables and a P<0.05 is considered to indicate statistical significance.
